2026, Food and Drug Administration and Side effects

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2026

Food and Drug Administration

Side effects

BMS strikes $14bn deal for Karuna Therapeutics

European Pharmaceutical Review

DECEMBER 22, 2023

It has demonstrated improvements in cognition and is not associated with common side effects of currently approved treatments like weight gain. Currently under review by the US Food and Drug Administration (FDA), KarXT is expected to launch in the US in late 2024.

Food and Drug Administration

Food and Drug Administration Side effects Safety Food

FDA makes moves to advance ALS research ahead of upcoming Amylyx AdCom

Pharmaceutical Technology

AUGUST 12, 2022

In the lead-up to a critical meeting that will influence the approval of a new drug for amyotrophic lateral sclerosis (ALS), the US Food and Drug Administration (FDA) has detailed its plans to advance rare neurodegenerative disease research. The first AdCom was critical of the study’s robustness. The FDA’s action plan.

FDA

FDA Food and Drug Administration Physicians Side effects

Pharma Rep Focus

BMS strikes $14bn deal for Karuna Therapeutics

FDA makes moves to advance ALS research ahead of upcoming Amylyx AdCom

Stay Connected